Ocuphire Pharma, Inc.
NASDAQ:OCUP
1.17 (USD) • At close October 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ocuphire Pharma, Inc. |
Symbool | OCUP |
Munteenheid | USD |
Prijs | 1.17 |
Beurswaarde | 31,737,184 |
Dividendpercentage | 0% |
52-weken bereik | 1.072 - 3.399 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Richard J. Rodgers M.B.A. |
Website | https://www.ocuphire.com |
An error occurred while fetching data.
Over Ocuphire Pharma, Inc.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)